Results 41 to 50 of about 76,806 (261)

Non-Hodgkin lymphoma

BMJ, 2018
The term non-Hodgkin lymphoma (NHL) covers a spectrum of malignant disorders arising from cells of the immune system and manifesting predominantly as lymphadenopathy or solid tumour. The classification of NHL is complex and ever-evolving, with more than 50 different subtypes listed in the latest WHO classification of lymphoma (1).
Bowzyk Al-Naeeb, Anna, Ajithkumar, Thankamma, Behan, Sarah, Hodson, Daniel James   +3 more
openaire   +3 more sources

AARS1‐Mediated RUNX3 K193 Lactylation Enhances the Activation and Cytotoxicity of CD8+T Cells in Smoking‐Related Emphysema

Advanced Science, EarlyView.
Exposure to CS causes an elevation of AARS1 levels, which increases the levels of RUNX3 lactylation at the K193 site and increases protein levels of RUNX3 through inhibition of autolysosomal degradation. Elevated RUNX3 levels promote CD8+T cell activation and augment their cytotoxicity, which induces alveolar epithelial cell death and facilitates the ...
Ying Zhu, Jiaheng Lin, Yifan Li, Qiaoqiao Zhou, Min Yu, Cheng Cheng, Kang Chang, Dang Lin, Tao Bian, Yan Wu, Lu Lu, Haibo Xia, Qizhan Liu   +12 more
wiley   +1 more source

Primary non-hodgkin′s lymphoma of bone: Experience of a decade

Indian Journal of Pathology and Microbiology, 2010
Objective: To study the prevalence and characterization of primary non Hodgkin′s lymphoma of bone in a major referral center of Pakistan. Methodology: All cases of primary non Hodgkin′s lymphoma of bone, diagnosed at a referral center in ...
Qureshi Asim, Ali Anum, Riaz Nashmia, Pervez Shahid   +3 more
doaj  

Cardiovascular Toxicity Associated With Bispecific Antibodies in Hematological Malignancies: A Comprehensive Pharmacovigilance Analysis

American Journal of Hematology, EarlyView.
ABSTRACT Cardiovascular adverse events (CVAEs) associated with bispecific T‐cell engaging antibodies (BsAbs) have not been systematically investigated across approved agents. In this disproportionality analysis of FAERS (December 2014–September 2025), reports listing BsAbs as the primary suspected drug (n = 7647) were compared with all other drugs in ...
Malak Munir, Ahmed Sayed, Dae Hyun Lee, Sanam Ghazi, Mustafa M. Houmsse, Saad Badat, Abdul Moeed, Avirup Guha, Daniel Addison, Narendranath Epperla   +9 more
wiley   +1 more source

Association of HHV-6 with Hodgkin and non Hodgkin lymphoma

Iranian Journal of Microbiology, 2016
Background and Objectives: Human Herpes 6 virus (HHV-6) could remain latent and chronic in the host cells after primary infection. HHV-6 genome encodes certain trans activation proteins which may results in development of malignantlymphoma.
Hadis Kiani, Manoochehr Makvandi, Alireza Samarbafzadeh, Ali Teimoori, Niloofar Neisi, Hamideh Mehravaran, Hashem Radmehr, Zeinab Hosseini, Azadeh Haghi, Toran Shahani, Mehran Varnaseri, Nastaran Ranjbari   +11 more
doaj  

Brazilian experience using high dose sequential chemotherapy followed by autologous hematopoietic stem cell transplantation for malignant lymphomas

Revista Brasileira de Hematologia e Hemoterapia, 2011
OBJECTIVE: To evaluate the use of high-dose sequential chemotherapy in a Brazilian population. METHODS: High-dose cyclophosphamide followed by autologous hematopoietic stem cell transplantation is an effective and feasible therapy for refractory/relapsed
Bruno Kosa Lino Duarte, Eliana Cristina Martins Miranda, Marcio Nucci, Afonso Celso Vigorito, Francisco José Penteado, José Francisco Comenalli Marques Jr, Gislaine Borba Oliveira-Duarte, Irene Gyongyver Heidemarie Lorand-Metze, Katia Borgia Pagnano, Marcia Torresan Delamain, Renata Baldissera, Isabella Salvetti Valente, Carmino Antonio de Souza   +12 more
doaj   +1 more source

Single‐Cell Level Characterization of B Cell Depletion and Repopulation Following Rituximab in Systemic Lupus Erythematosus

Arthritis &Rheumatology, EarlyView.
Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang, Norzawani Buang, Catherine Sutherland, Wanseon Lee, Lauren Overend, Tarran S. Rupall, Katie L. Burnham, Matthew C. Pickering, Marina Botto, Emma E. Davenport   +9 more
wiley   +1 more source

Distinct Molecular Pathways Supporting Sjögren Disease Clusters and Disease Progression

Arthritis &Rheumatology, EarlyView.
Objective Sjögren disease (SjD) is a heterogeneous autoimmune disease. We aimed to investigate blood transcriptomic signatures and disease progression among three recently defined clusters of patients with SjD: (1) B cell active disease with low symptom burden (BALS), (2) high systemic activity (HSA), and (3) low systemic activity with high symptom ...
Sacha E. Silva‐Saffar, Yann Nguyen, Raphaèle Seror, Jacques‐Eric Gottenberg, Anna Niarakis, Xavier Mariette, Gaetane Nocturne   +6 more
wiley   +1 more source

Peripheral Blood DNA Methylation Changes Precede Lymphoma Diagnosis in Primary Sjögren's Disease

Arthritis &Rheumatology, EarlyView.
Objective Primary Sjögren's disease (SjD) is a systemic autoimmune disease associated with an increased risk of lymphoma. The molecular mechanisms underlying lymphomagenesis remain poorly understood, and sensitive biomarkers for early identification of patients at high risk of developing lymphoma are lacking.
Hanna Lidberg, Cecilia Fugmann, Juliana Imgenberg‐Kreuz   +2 more
wiley   +1 more source

Comparative global burden analysis of lymphoma subtypes: a statistical evaluation of severity across global regions

Frontiers in Public Health
IntroductionVarious subtypes of lymphoma, including Hodgkin lymphoma, non-Hodgkin lymphoma, and Burkitt lymphoma, impose a significant global health burden.
Yu Liang, Yu Liang, Yingying Tang, Yingying Tang, Yuanyuan WanYan, Yuanyuan WanYan, Erwei Li, Erwei Li   +7 more
doaj   +1 more source